In an analogous study, RIPerC therapy also improved the cerebral blood flow (CBF) and the hemorrhage, edema, and neurobehavioral outcomes significantly on top of the reduction in infarction size compared to IV-tPA alone at 4 h post-stroke (95). This evidence concerns the gene PLAT and stroke disorder.